New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
05:41 EDTBIIBBiogen, Eisai enter collaboration develop, commercialize Alzheimerís treatments
Eisai and Biogen Idec announced that they have entered into a collaboration to develop and commercialize two of Eisaiís clinical candidates for Alzheimerís disease, or AD, E2609 and BAN2401. The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idecís candidates for AD, the anti-amyloid beta antibody BIIB037 and an anti-tau monoclonal antibody. The collaboration initially will be centered on the co-development and co-commercialization of Eisaiís two candidates: E2609, a beta-site amyloid precursor protein cleaving enzyme, or BACE, inhibitor, and BAN2401, an anti-amyloid beta antibody. These candidates have the potential to reduce amyloid beta plaques that form in the brains of patients with AD and to stop the formation of new plaques, potentially improving symptoms and suppressing disease progression. Biogen Idec will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments. The agreement also includes options for Eisai to receive an additional one-time payment from Biogen Idec related to joint development and commercialization activities in Japan.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 6, 2015
07:04 EDTBIIBIsis Pharmaceuticals earns $9M for advancing ISIS=SMN Rx
Subscribe for More Information
February 27, 2015
07:37 EDTBIIBBiogen removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
07:19 EDTBIIBBiogen, Sobi report Phase 3 Alprolix paediatric study meets primary endpoint
Subscribe for More Information
07:10 EDTBIIBBiogen Idec, Swedish Orphan Biovitrum AB announce positive Alprolix results
Subscribe for More Information
February 26, 2015
08:15 EDTBIIBBiogen shares likely to continue to advance, says RBC Capital
Subscribe for More Information
February 25, 2015
06:14 EDTBIIBPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use